MNPR
Price
$108.35
Change
-$6.31 (-5.50%)
Updated
Jul 31 closing price
Capitalization
725.84M
3 days until earnings call
Intraday BUY SELL Signals
QNCX
Price
$23.39
Change
+$0.36 (+1.56%)
Updated
Jul 31 closing price
Capitalization
22.87M
8 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

MNPR vs QNCX

MNPR vs QNCX Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
MNPR vs. QNCX commentary
Aug 03, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is MNPR is a Hold and QNCX is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 03, 2026
Stock price -- (MNPR: $108.35 vs. QNCX: $23.39)
Brand notoriety: MNPR and QNCX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: MNPR: 144% vs. QNCX: 47%
Market capitalization -- MNPR: $725.84M vs. QNCX: $22.87M
MNPR [@Biotechnology] is valued at $725.84M. QNCX’s [@Biotechnology] market capitalization is $22.87M. The market cap for tickers in the [@Biotechnology] industry ranges from $121.09B to $0. The average market capitalization across the [@Biotechnology] industry is $2.06B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

MNPR’s FA Score shows that 1 FA rating(s) are green whileQNCX’s FA Score has 1 green FA rating(s).

  • MNPR’s FA Score: 1 green, 4 red.
  • QNCX’s FA Score: 1 green, 4 red.
According to our system of comparison, MNPR is a better buy in the long-term than QNCX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

MNPR’s TA Score shows that 3 TA indicator(s) are bullish while QNCX’s TA Score has 5 bullish TA indicator(s).

  • MNPR’s TA Score: 3 bullish, 5 bearish.
  • QNCX’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, QNCX is a better buy in the short-term than MNPR.

Price Growth

MNPR (@Biotechnology) experienced а -1.38% price change this week, while QNCX (@Biotechnology) price change was +31.00% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -1.22%. For the same industry, the average monthly price growth was -8.12%, and the average quarterly price growth was +2790.29%.

Reported Earning Dates

MNPR is expected to report earnings on Aug 06, 2026.

QNCX is expected to report earnings on Aug 11, 2026.

Industries' Descriptions

@Biotechnology (-1.22% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
MNPR($726M) has a higher market cap than QNCX($22.9M). MNPR YTD gains are higher at: 65.926 vs. QNCX (-96.509). MNPR has higher annual earnings (EBITDA): -18.71M vs. QNCX (-48.46M). MNPR has more cash in the bank: 137M vs. QNCX (3.02M). MNPR has less debt than QNCX: MNPR (132K) vs QNCX (406K). MNPR (0) and QNCX (0) have equivalent revenues.
MNPRQNCXMNPR / QNCX
Capitalization726M22.9M3,170%
EBITDA-18.71M-48.46M39%
Gain YTD65.926-96.509-68%
P/E RatioN/AN/A-
Revenue00-
Total Cash137M3.02M4,533%
Total Debt132K406K33%
FUNDAMENTALS RATINGS
MNPR vs QNCX: Fundamental Ratings
MNPR
QNCX
OUTLOOK RATING
1..100
6450
VALUATION
overvalued / fair valued / undervalued
1..100
39
Fair valued
18
Undervalued
PROFIT vs RISK RATING
1..100
32100
SMR RATING
1..100
96100
PRICE GROWTH RATING
1..100
3459
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

QNCX's Valuation (18) in the Biotechnology industry is in the same range as MNPR (39) in the null industry. This means that QNCX’s stock grew similarly to MNPR’s over the last 12 months.

MNPR's Profit vs Risk Rating (32) in the null industry is significantly better than the same rating for QNCX (100) in the Biotechnology industry. This means that MNPR’s stock grew significantly faster than QNCX’s over the last 12 months.

MNPR's SMR Rating (96) in the null industry is in the same range as QNCX (100) in the Biotechnology industry. This means that MNPR’s stock grew similarly to QNCX’s over the last 12 months.

MNPR's Price Growth Rating (34) in the null industry is in the same range as QNCX (59) in the Biotechnology industry. This means that MNPR’s stock grew similarly to QNCX’s over the last 12 months.

MNPR's P/E Growth Rating (100) in the null industry is in the same range as QNCX (100) in the Biotechnology industry. This means that MNPR’s stock grew similarly to QNCX’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
MNPRQNCX
RSI
ODDS (%)
Bearish Trend 4 days ago
90%
Bearish Trend 4 days ago
83%
Stochastic
ODDS (%)
Bearish Trend 4 days ago
90%
Bearish Trend 4 days ago
87%
Momentum
ODDS (%)
Bearish Trend 4 days ago
84%
Bullish Trend 4 days ago
89%
MACD
ODDS (%)
Bearish Trend 4 days ago
84%
N/A
TrendWeek
ODDS (%)
Bearish Trend 4 days ago
90%
Bullish Trend 4 days ago
83%
TrendMonth
ODDS (%)
Bullish Trend 4 days ago
81%
Bullish Trend 4 days ago
84%
Advances
ODDS (%)
Bullish Trend 8 days ago
84%
Bullish Trend 4 days ago
82%
Declines
ODDS (%)
Bearish Trend 6 days ago
89%
Bearish Trend 8 days ago
90%
BollingerBands
ODDS (%)
N/A
Bearish Trend 4 days ago
83%
Aroon
ODDS (%)
Bullish Trend 4 days ago
77%
Bullish Trend 4 days ago
80%
View a ticker or compare two or three
Interact to see
Advertisement
MNPR
Daily Signal:
Gain/Loss:
QNCX
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
EMGNX40.650.84
+2.11%
Allspring Emerging Markets Equity Inst
VRGWX936.977.54
+0.81%
Vanguard Russell 1000 Growth Index I
MBINX33.470.05
+0.15%
NYLI Balanced Investor Class
WSMRX30.18-0.06
-0.20%
William Blair Small-Mid Cap Growth R6
BNIEX13.73-0.12
-0.87%
UBS International Sustainable Equity A

MNPR and

Correlation & Price change

A.I.dvisor indicates that over the last year, MNPR has been loosely correlated with QNCX. These tickers have moved in lockstep 36% of the time. This A.I.-generated data suggests there is some statistical probability that if MNPR jumps, then QNCX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MNPR
1D Price
Change %
MNPR100%
-5.50%
QNCX - MNPR
36%
Loosely correlated
+1.56%
ROIV - MNPR
35%
Loosely correlated
-1.77%
GMAB - MNPR
32%
Poorly correlated
+0.80%
TSHA - MNPR
32%
Poorly correlated
-0.26%
KROS - MNPR
30%
Poorly correlated
-1.47%
More